Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | OTX-2002 |
Synonyms | |
Therapy Description |
OTX-2002 is an mRNA therapeutic that targets the insulated genomic domain of the MYC gene and leads to decreased MYC mRNA and protein levels, potentially resulting in reduced cell proliferation of tumor cells and inhibition of tumor growth (Annals of Oncology 33 (2022): S355). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
OTX-2002 | OTX2002|OTX 2002 | OTX-2002 is an mRNA therapeutic that targets the insulated genomic domain of the MYC gene and leads to decreased MYC mRNA and protein levels, potentially resulting in reduced cell proliferation of tumor cells and inhibition of tumor growth (Annals of Oncology 33 (2022): S355). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT05497453 | Phase Ib/II | OTX-2002 | A Phase 1/2 Study to Evaluate OTX-2002 in Patients With Hepatocellular Carcinoma and Other Solid Tumor Types Known for Association With the MYC Oncogene (MYCHELANGELO I) | Recruiting | USA | 4 |